# Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%

> **NCT02269163** · PHASE3 · COMPLETED · sponsor: **Prometic Biotherapeutics, Inc.** · enrollment: 82 (actual)

## Conditions studied

- Primary Immunodeficiency

## Interventions

- **BIOLOGICAL:** Immune Globulin Intravenous
- **BIOLOGICAL:** Prometic's Immune Globulin Intravenous 10%

## Key facts

- **NCT ID:** NCT02269163
- **Lead sponsor:** Prometic Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-26
- **Primary completion:** 2019-01-11
- **Final completion:** 2019-01-11
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2021-11-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02269163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02269163, "Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02269163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*